Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Operations: 2020-2025

Historic Cash from Operations for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$18.9 million.

  • Foghorn Therapeutics' Cash from Operations rose 10.21% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.3 million, marking a year-over-year increase of 14.58%. This contributed to the annual value of -$100.4 million for FY2024, which is 14.99% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' Cash from Operations stood at -$18.9 million, which was up 10.19% from -$21.0 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Cash from Operations peaked at $271.5 million during Q1 2022, and registered a low of -$32.2 million during Q2 2023.
  • In the last 3 years, Foghorn Therapeutics' Cash from Operations had a median value of -$25.5 million in 2024 and averaged -$25.7 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Cash from Operations tumbled by 852.09% in 2021 and then surged by 1,273.09% in 2022.
  • Foghorn Therapeutics' Cash from Operations (Quarterly) stood at $11.9 million in 2021, then slumped by 343.43% to -$28.9 million in 2022, then increased by 4.78% to -$27.5 million in 2023, then grew by 10.97% to -$24.5 million in 2024, then increased by 10.21% to -$18.9 million in 2025.
  • Its Cash from Operations stands at -$18.9 million for Q3 2025, versus -$21.0 million for Q2 2025 and -$24.0 million for Q1 2025.